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A report on the FASEB Summer Research Conference on
Autoimmunity, Saxtons River, USA, 14-29 July 2007.
We have long known that there are both genetic and non-
genetic components in autoimmune disease. Although under-
lying genetic contributions can increase the likelihood of
developing autoimmune disease, they do not ensure it, imply-
ing that environmental components also affect the outcome.
The major themes for this year’s FASEB conference on
autoimmunity were the emerging data on genetic poly-
morphisms linked with human autoimmune disease, and
recent developments in our current understanding of immune
mechanisms implicated in autoimmune disease. This report
focuses on how we can begin to integrate the new genetic
data into our current understanding of normal and patho-
logical immune processes.
Genome-wide linkage analysis
As pointed out by Joan Goverman (University of Washington,
Seattle, USA), we now know that human autoimmune
diseases are truly diseases of immune dysfunction. The proof
of this lies in the genes that have recently been associated
with the development of multiple sclerosis (MS), type 1
diabetes, systemic lupus erythematosis (SLE), Crohn’s disease
(CD) and rheumatoid arthritis (RA). Interestingly, some of
the predisposing genes are shared between different
diseases, suggesting common mechanisms underlying the
pathology of these diseases. There are also unique genetic
components, however, indicating that distinct pathways are
contributing to the etiology of each disease.
Large groups of researchers have now come together to share
populations of patients and identify genetic linkages using
large-scale analysis of single-nucleotide polymorphisms
(SNPs). The power of this approach is that it is hypothesis-
neutral, and large datasets allow the detection of the weaker
genetic linkages found for complex multigenic traits. David
Hafler (Harvard Medical School, Boston, USA) previewed data
from the International Multiple Sclerosis Genetics
Consortium. In this study, 931 MS patients and their parents
were evaluated for SNPs using DNA microarrays. Additional
MS families and healthy controls were tested for replication of
the findings, and the likelihood of association of a given SNP
polymorphism with MS was determined. As expected, the
HLA locus had the largest association with MS, underscoring
the point that the immune system contributes to disease
predisposition. The exciting news was that additional genes of
immune function are also associated with MS. The most
significant linkages were seen with genes for the alpha chain of
the IL2 receptor (IL2RA) and the receptor for IL7. The
cytokines IL2 and IL7 are both associated with homeostasis of
lymphocyte populations, with IL2 being particularly
implicated in the function of regulatory T cells (Treg).
Additional intriguing candidate gene associations that need
further replication include KIAA0350, a gene of unknown
function expressed in immune cells, and CD58, encoding a
ligand for the activation receptor CD2 on T cells.
Both shared and unique genes are linked with individual auto-
immune diseases. Linda Wicker (University of Cambridge, UK)
summarized current finding on genetic linkages with type 1
diabetes. Here again, the HLA class II region is most highly
associated with disease predisposition and, as in MS, the
IL2RA gene is linked with type 1 diabetes. The insulin locus is
implicated as a gene uniquely linked with type 1 diabetes. The
R620W allele of protein tyrosine phosphatase 22 (PTPN22) is
associated with type-1 diabetes. PTPN22 binds to CSK kinase
and this complex negatively regulates T-cell signaling. The
R620W mutation results in disrupted binding of PTPN22 to
CSK kinase, suggesting that this polymorphism may result in
alterations in T-cell activation to autoimmune stimuli. R620W
is also associated with RA, but not with MS. In contrast,
CTLA4, another negative regulator of T-cell activation, is
associated with type 1 diabetes, but not with MS or RA. The fact
that distinct immune-function genes are linked with specific
diseases probably points to differences in the influence of
individual immune-response genes in the disease etiology.Gene function in animal models of autoimmune
disease
Why are these predisposing genes associated with auto-
immunity? For this, we turn to the discussions of immune
mechanisms associated with autoimmunity. The analysis of
genetic contributions to autoimmune disease susceptibility
in animal models is one approach to understanding how
underlying genetic changes may contribute to disease. These
genes then have to be placed in the context of the immune
mechanisms that contribute to autoimmune disease.
The HLA complex is identified as a susceptibility locus in
many autoimmune diseases, underscoring the likely require-
ment for T-cell-dependent adaptive immune responses in
autoimmunity. Goverman presented results on the develop-
ment of experimental autoimmune encephalomyelitis (EAE)
in two strains of mice that are congenic except for
differences at the MHC class II locus. Both mice made CD4+
T-cell responses to myelin oligodendrocyte glycoprotein
peptides, although the T cells from each strain recognized
distinct immunodominant peptides. This difference in the
autoreactive T-cell response resulted in dramatic differences
in the course of the disease, with one strain exhibiting
classical EAE with ascending paralysis, whereas the other
strain had atypical EAE. The current emphasis of these
studies is on understanding the pattern of trafficking of
these T cells into the central nervous system, and on the
phenotype of the pathogenic cells. As discussed by Steve
Miller (Northwestern University, Chicago, USA), activation
of pathogenic T cells in EAE can occur within the central
nervous system, and the precise conditions of those priming
events can result in distinct disease outcomes. One can
extrapolate from these results in animals to considering the
effects of small changes in HLA loci on autoimmune disease
in humans. Thus, polymorphisms in HLA may not only be
permissive for disease, but may also influence disease
manifestations.
Genetic mapping studies have also uncovered linkages to
immune-function genes in animal models of SLE. Ward
Wakeland (University of Texas Southwestern Medical
Center, Dallas, USA) reported on the genetics of animal
models of SLE. In these studies, allelic regions are isolated
from complex resistant and susceptible genetic back-
grounds. The SLE1 region was identified on chromosome 1
from the lupus prone strain NZM2410, and is associated
with an increased expression of anti-chromatin autoanti-
bodies. Genes encoding members of the SLAM family of
receptors are located in this region. The Ly108 gene has
been implicated in contributing to the loss of B cell tolerance
in the susceptible strain. Additional candidate genes in this
region include Ly9 and CD84. This region is of particular
interest, as a syntenic region in human shows some evidence
of linkage in SLE. Toll-like receptors (TLRs) have been
implicated in animal models of SLE, as highlighted by Mark
Shlomchik (Yale University, New Haven, USA). In the MRL-
lpr mouse model of SLE, deficiency in TLR9 resulted in
attenuated auto-antibody responses to chromatin and
double-stranded DNA, whereas deficiencies in TLR7 were
associated with decreased autoantibody responses to RNA
antigens. However, deficiency in TLR9 was associated with
increased clinical signs of lupus nephritis in these mice,
whereas deficiency in TLR7 was protective. Thus, genetic
alterations in specific TLR receptors can affect distinct
disease parameters. Ann Marshak-Rothstein (Boston Univer-
sity, USA) presented recent results identifying a role for the
receptor for advanced glycation end products (RAGE) and its
ligand HMGB1 (amphoterin) in the activation of autoreactive
B cells in SLE models. These studies suggest that innate
immune pathways may contribute to SLE pathology.
Co-stimulation and autoimmunity
The CD28 gene family and their B7 family ligands are critical
for controlling normal immune responses, and have been
implicated in animal models of autoimmune disease. Arlene
Sharpe (Harvard Medical School) reported on the current
state of knowledge of the B7 and CD28 gene families,
including an unexpected finding that mouse PD-L1, a B7
family ligand for the PD-1 receptor, can also interact with
B7-1 (CD80), another B7 family ligand. Measurements of the
avidities of B7.1 and PD-L1, in the form of dimeric fusion
proteins with Fc portion of IgG, suggest that B7.1 binds PD-
L1 with an avidity intermediate between its avidity for CD28
and CTLA4. Thus, in considering the effects of the CTLA4
polymorphisms in autoimmunity, one must integrate this
shared ligand paradigm for B7.1 binding to CD28, CTLA4,
and now PD-L1. The costimulatory receptor ICOS has been
shown to be important for IL21 production by follicular T
helper cells, as discussed by Joe Craft (Yale University),
providing a possible biological rationale for a linkage with
antibody dependent autoimmune disease. IL21 has also been
implicated in animal models of type 1 diabetes, RA and SLE.
Another gene possibly associated with type 1 diabetes in the
studies discussed by Wicker is CD226, which encodes an
immunoglobulin superfamily member that has been identified
as a co-stimulatory receptor. Ligands for this protein are the
immunoglobulin superfamily members PVR and CD112
(Nectin 2). Steve Levin (ZymoGenetics, Seattle, USA)
reported on a new receptor for PVR and CD112 - Vsig9. His
results support a negative regulatory function for this new
receptor. Together, these results now link this receptor-
ligand complex with type 1 diabetes.
Regulatory Tcells and Th17 cells: new lineages
of T cells
A key theme of the conference was the balance between
regulatory T cells (Treg) and a newly identified lineage of
effector CD4 T cells called Th17 cells. Th17 cells are charac-
terized by the production of the cytokines IL17A, IL17F and
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In contrast, Treg cells are thought to be critical for the main-
tenance of tolerance and for limiting immune responses. The
importance of Treg in humans is underscored by identification
of mutations in FoxP3, a transcription factor required for Treg
function, in patients with the autoimmune disease IPEX
(immunodysregulation, polyendocrinopathy and enteropathy).
Deficiency in FoxP3 results in an autoimmune phenotype
that is lethal in childhood if untreated. In numerous mouse
models, Treg cells have been found to modulate susceptibility
to autoimmune disease as well as disease course.
Both Treg and Th17 cells require transforming growth factor
beta (TGFβ) for their differentiation, but the presence of IL6
biases towards development of a Th17 response. Richard
Flavell (Yale University) presented data from TGFβ
conditional knockout mice, demonstrating that TGFβ made
by T cells is critical for the development of Th17 cells. In
contrast, T-cell derived TGFβ is not required for
development of Treg, implying that other sources of TGFβ
can suffice. Vijay Kuchroo (Harvard Medical School)
discussed new results showing that IL21 can also contribute
to the development of Th17 cells, providing one possible
rationale for the linkage of the IL21 locus to autoimmunity in
animal models.
Rachel Caspi (National Eye Institute, NIH, Bethesda, USA)
presented results showing that Th17 cells contribute to the
pathology of experimental autoimmune uveitis (EAU), an
autoimmune inflammation of the eye, in mice. Interestingly,
although antibodies to IL17A block EAU, IL17A-deficient
mice appear to be susceptible to EAU. Thus, multiple
effector molecules must contribute to this disease, and in the
absence of IL17A, a distinct autoimmune profile must
emerge. This illustrates the importance of genetic context in
querying the contribution of a particular mediator.
It is interesting that CD25, the high-affinity receptor for IL2, is
linked to multiple human autoimmune diseases. CD25 is
expressed on Treg cells, and IL2 is required for Treg function. As
outlined by Calliope Dendrou (University of Cambridge),
current efforts are directed towards understanding how CD25
polymorphisms may influence Treg and T-cell effector
functions. In preliminary studies, normal human volunteers
bearing susceptibility alleles at CD25 were found to express
lower levels of CD25 on the surface of their Treg cells. The
CD25 susceptibility allele was also correlated with lower levels
of soluble CD25 in serum. Functional studies on Treg will be
required to evaluate how this may influence T cell responses.
Our ability to intervene in autoimmune diseases will be
greatly enhanced by an understanding of the roles of these
genetic pathways in normal immune responses. With new
tools, such as the ability to image responding immune cells
using intravital microscopy, as elegantly presented by Ron
Germain (National Institute of Allergy and Infectious Diseases,
NIH, Bethesda, USA) and Uli von Andrian (Harvard Medical
School), we can now begin to visualize immune responses in
vivo. Ron Germain highlighted his recent findings
examining migration of T and B cells in lymph nodes in vivo.
These studies are done by labeling cell populations with
fluorescent tags that can be visualized directly in lymph
nodes using confocal and multiphoton intravital microscopy.
T cells were visualized migrating along fibroblastic reticular
networks, whereas follicular B cells migrated along a distinct
dendritic follicular network. These studies are now being
extended to examine the migration of antigen-specific CD4
and CD8 T cells and B cells in response to antigen associated
with dendritic cells. This work allows a more accurate picture
of how an immune response occurs in space and time within
the lymphoid tissues.
Using similar methodologies, Uli von Andrian has begun to
examine cellular interactions in the context of viral infection.
Injection of fluorescently labeled VSV virus in mice resulted
in capture of the virus by a distinct population of CD169+
macrophages in the draining the lymph nodes. These cells
then presented antigen to B cells within the nodes, allowing
for initiation of an anti-viral immune response.
As the in vivo architecture of the immune response becomes
defined, one can predict that genetic variation will also
impact the spatial and kinetic aspects of this response. These
techniques will allow acquisition of new information about
how immune responses are regulated by specific genes.
What are the implications of finding that predisposing genes
are immune-function genes? One is that multiple small
changes in the function of certain immune proteins can lead
to profound changes in our response to immune stimuli.
Each of the polymorphisms detected could result in a func-
tional, but slightly different, immune response. Under the
right conditions, and with the right mixture of complex
genes, these small changes are enough to tip the balance.
Another indication from these results is that immune stimuli
are implicated in the initiation of autoimmune diseases,
supporting the hypothesis that infectious diseases or other
inflammatory events may be temporally linked to the
initiation of autoimmune disease.
Why have we retained these predisposing genes in the general
population? Profound changes are likely to be selected against,
as survival from infectious disease would be compromised.
Rather, these smaller changes may have been selected to allow
greater survival in endemic diseases such as tuberculosis or
malaria. Understanding the pathological processes that drive
autoimmune disease may allow us to target therapy more
precisely and allow us to identify those patients who can
respond to particular therapeutic options, without compro-
mising their ability to respond to infectious disease.
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